<DOC>
	<DOCNO>NCT02403362</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy， pharmacodynamics ( PD ) , pharmacokinetics ( PK ) multiple intravenous dos EPO-018B participant chronic kidney disease ( CKD ) Who dialysis</brief_summary>
	<brief_title>Safety &amp; Efficacy EPO-018B Treatment Anemia Participants With Chronic Kidney Diseases Not Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>1 . Males females ≥18 and≤70 . 2 . Chronic renal disease stage 3 4 ( estimate Glomerular Filtration Rate ( eGFR ) 15 60 ml/min per 1.73 m2 use CKDEPI equation ) expect need dialysis study . 3 . Patients receive erythropoietic agent within 6 week prior first study dose . 4 . Two hemoglobin value ≥ 6.0 &lt; 10.0 g/dL Screening 5 . Patients transferrin saturation ≥ 20 % ferritin ≥ 100 ng/mL . vitamin B12 folic acid level lower limit normal . 6 . Signed informed consent . 1 . Pregnant lactating female . 2 . Red blood cell transfusion within 3 month prior study drug administration . 3 . Known intolerance erythropoiesis stimulate agent ( ESA ) pegylated molecule parenteral iron supplementation product . 4 . Hemolytic syndrome coagulation disorder . 5 . Hematological disease ( include limit myelodysplastic syndrome , hematological malignancy , hemoglobinopathy , pure red cell aplasia ) . 6 . Chronic , uncontrolled , symptomatic inflammatory disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosus , etc. ) . 7 . C reactive Protein ( CRP ) level great 30 mg/L within 4 week prior study drug administration . 8 . Uncontrolled symptomatic secondary hyperparathyroidism ( iPTH &gt; 500pg/ml ) . 9 . Poorly control hypertension within 2 week prior study drug administration , per investigator 's clinical judgment ( e.g . systolic ≥ 160mm Hg , diastolic ≥ 100 mm Hg ) 10 . Chronic congestive heart failure ( New York Heart Association Class IV ) . 11 . Significant symptom within 6 month prior study drug administration ( e.g . myocardial infarction , serious precarious coronary artery disease , stroke , respiratory disease , autoimmune disease , neuropathy , phrenopathy , hepatopathy include Active hepatitis B , Active hepatitis C , ALT &gt; 3 x upper limit normal ( ULN ) , AST &gt; 3 x upper limit normal ( ULN ) , etc. ) . 12 . A positive test HIV antibody . 13 . Tumor malignancy . 14 . Expected survival le 12 month . 15 . Major surgery ( may Massive bleeding ) study . 16 . Expected conception within 4 Weeks end Study Treatment . 17 . The subject participate clinical trial within 6 week prior study drug administration . 18 . Have condition prior therapy , investigator 's opinion , would make subject unsuitable study , unable unwilling comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>